BurakZeybekMDCritical Care Medicine

Obstetrics & Gynecology • Gainesville, FL

Gynecologic Oncology

Assistant Professor

Join to view full profile

Dr. Zeybek is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zeybek's full profile

Already have an account?

Office
1549 Gale Lemerand Dr
Gainesville, FL 32610
Phone+1 352-265-8200

Education & Training

Yale-New Haven Medical CenterFellowship, Critical Care Medicine (Anesthesiology), 2021 - 2022
Yale-New Haven Medical CenterFellowship, Gynecologic Oncology, 2018 - 2021
University of Texas Medical Branch HospitalsResidency, Obstetrics and Gynecology, 2014 - 2018
Istanbul University FomClass of 2005

Certifications & Licensure

FL State Medical License 2022 - 2026
CT State Medical License 2017 - 2023
American Board of Obstetrics and Gynecology Obstetrics & Gynecology

Publications & Presentations

PubMed

Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi
British Journal of Cancer. 2024-04-01
Alterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System-A Case Report.
Tyler Wahl, Angela Stokes, Caleb Varner, Burak Zeybek, Amit Bardia
The Journal of Extra-Corporeal Technology. 2022-09-01
6 citations
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi
British Journal of Cancer. 2022-06-01

Lectures

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

More HPV Pathology with Single-Dose VaccineMarch 12th, 2017